Adynovate FDA Approval History
Adynovate (antihemophilic factor (recombinant) pegylated) is a human antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A.
Development timeline for Adynovate
|Dec 27, 2016
|Approval Shire Announces FDA Approval of Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical Settings
|Nov 13, 2015
|Approval FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.